Efficacy, Safety, and Confirmation of the Recommended Phase 2 Starting Dose of the Combination of Ruxolitinib (RUX) and Panobinostat (PAN) in Patients (Pts) with Myelofibrosis (MF)
Claire Harrison(Guy's and St Thomas' NHS Foundation Trust), Vincent Ribrag(Institut Gustave Roussy), Jean‐Jacques Kiladjian(Délégation Paris 5), Francesco Passamonti(University of Milan), Tracy Liu(West Virginia University), Daniel B. Lipka(German Cancer Research Center), Suddhasatta Acharyya(Novartis (United States)), Eibhlin Conneally(St. James's Hospital), Alessandro M. Vannucchi(Azienda Ospedaliero-Universitaria Careggi), Song Mu, Florian H. Heidel(Medizinische Hochschule Hannover), Bruno Martino(Azienda ospedaliera "Bianchi-Melacrino-Morelli"), Amjad Hayat(Ollscoil na Gaillimhe – University of Galway), Thomas Kindler(German Cancer Research Center), Prashanth Gopalakrishna(Novartis (Switzerland)), Susan Ide(Novartis (United States))
Cited by 39
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Somatic <i>CALR</i> Mutations in Myeloproliferative Neoplasms with Nonmutated <i>JAK2</i>
|New England Journal of Medicine|2013|1.7k
Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant Erythropoietin
|New England Journal of Medicine|2002|1.2k